Eslicarbazepine acetate: Phase III data

Pooled data from 3 double-blind, placebo-controlled, international Phase III trials of once-daily, eslicarbazepine in >1,000 patients, showed that 800 and 1200 mg reduced seizure frequency by >33% ove...